



Stock Code : 4180

TWi Pharmaceuticals, Inc.

Notice of 2018 Annual Shareholders' Meeting (Summary translation)

- I. The 2018 Annual Shareholders' Meeting (the "Meeting") will be convened at 2F., No.327, Sec. 1, Tiding Blvd., Neihu Dist., Taipei City (The shareholders meeting admission time will start at 08:30 a.m. at the meeting venue) at 9:00 a.m. on June 8, 2018 (Friday). The agenda for the Meeting is as follows:
 1. Reports on Company Affairs :
 - (1) 2017 Business Report.
 - (2) 2017 Audit Committee's Review Report.
 - (3) Report on Accumulated Losses Reaching One-Half of Paid-in Capital and Execution of the Improvement Plan of the Operation for the fourth quarter 2017.
 - (4) Report on the Execution for Share Buyback Program.
 2. Proposals :
 - (1) Adoption of the 2017 Business Report, Financial Statements and Consolidated Financial Statements.
 - (2) Adoption of the Proposal for 2017 Deficit Compensation.
 3. Elections :
 - (1) Election of the 10th Term Board of Directors (including independent directors).
 4. Others :
 - (1) Proposal of Release the Prohibition on Directors or Representatives of Directors from Participation in Competitive Business.
 5. Questions and Motions
 6. Adjournment

II. Non-competition restrictions on the directors to be released:

1. Pursuant to Article 209 of the Company Act, a director who “acts for himself or on behalf of another person, and whose act falls within the scope of the company’s business, shall explain at the meeting of the shareholders the essential details of such act and obtain approval at the shareholders’ meeting.
2. In order to be aided from the professional expertise and relevant experience of the Company's directors, and under the premise of no violation to the interests of the Company, it was requested that the Shareholders' Meeting agree on releasing the non-competition restrictions of the Company's Directors (including independent directors). The act of participation in competitive business of the Directors candidates is as in the following table:

Name of director	Act of participation in competitive business	Name of institutional shareholder represented	Business invested by such institutional shareholder
Chen, Chih-Ming	<ol style="list-style-type: none"> 1. Director of AG Global Inc. 2. Director of Ahura Assets Limited. 3. Chairman of Allgenesis Biotherapeutics, Inc. 4. Director of Calchen Holdings Co. Ltd. 5. Chairman of CM Chen Foundation Inc. 6. Director of Delightful Cheers Limited. 7. Director of Eldridge Capital Group Ltd. 8. Director of Great Success Holdings Ltd. 9. Director of Opulent Assets Holdings Ltd. 10. Director of Otago Heights Capital Ltd. 11. Director of Shining Armour Holding Inc. 12. Director of Summer Breeze Development Ltd. 13. Director of SW Pacific Investment Ltd. 14. Director of TWi Pharmaceuticals Holding Inc. 15. Director of Twin City Management Ltd. 16. Director of Hefei NORATECH Pharmaceutical Co. Ltd. 17. Chairman of TWi Biotechnology, Inc. 	-	-

	<p>18. Chairman of Xin Chen Pharmaceutical Foundation.</p> <p>19. Chairman of Xin Chen Investment Co., Ltd.</p> <p>20. Chairman & CEO of NRT Pharmaceuticals, Inc.</p>		
Ma, Hai-Yi	<p>1. Independent director of Crown Bioscience International.</p> <p>2. Executive Director of Taiwan Bio Industry Organization</p> <p>3. Director of Formosa Pharmaceuticals, Inc.</p> <p>4. Consultant of LifeMax Biotechnology, Inc.</p> <p>5. Director of Development Center for Biotechnology.</p> <p>6. Director of Reber Genetics Co., Ltd.</p>	Opulent Assets Holdings Ltd.	Director of AG Global Inc.
Huang, Wen-Hong	<p>1. Independent director of Taigen Biopharmaceuticals Holdings Limited.</p> <p>2. Corporate Director's Representative of Orient Pharma Co., Ltd.</p> <p>3. Corporate Director's Representative of Formosa Pharmaceuticals, Inc.</p> <p>4. Consultant of LifeMax Biotechnology, Inc.</p> <p>5. Director of Panion & Bf Biotech Inc.</p>	TWi Pharmaceuticals Holding Inc.	-
Liu, Nien-Hua	<p>1. Director of HBT Labs, Inc.</p> <p>2. Director of Genovi Co., Ltd,</p> <p>3. Chairman of Synpac-Kingdom Pharmaceuticals, Inc.</p> <p>4. Supervisor of Allgenesis Biotherapeutics, Inc.</p> <p>5. Director of NRT Pharmaceuticals, Inc.</p>	Opulent Assets Holdings Ltd.	Director of AG Global Inc.
Su, Yu-Hui	<p>1. Independent director of In Win Development Inc.</p> <p>2. Independent director of Makalot Industrial Co., Ltd.</p> <p>3. Independent director of Ennoconn Corporation.</p>	-	-
Sun, Ching-Feng	<p>1. Independent director of ASLAN Pharmaceuticals.</p>	-	-

	<ul style="list-style-type: none"> 2. Chairman of FiTek Photonics Corporation. 3. G.M. of Saga Unitek Ventures, Ltd. 4. G.M. of Kang-Cyun Ventures, Ltd. 5. G.M. of Sheng-Da Ventures, Ltd. 6. Supervisor of Pixon Technologies Corporation. 7. G.M. of Shun-Cheng-Fong Ventures, Ltd. 8. Independent director of Wonderful Hi-Tech Co., Ltd. 9. Independent director of Tah Tong Textile Co., Ltd. 10. Supervisor of Newmax Technology Co., Ltd. 11. Supervisor of Reber Genetics Co., Ltd. 		
Lin, Dong-Han	<ul style="list-style-type: none"> 1. Corporate Director's Representative of Formosa Laboratories, Inc., 2. Chairman of Alar Pharmaceuticals Inc. 	-	-

III. Please find the Notice of Attendance and Proxy Form enclosed with this Meeting Notice. If you plan to attend the meeting in person, please affix your signature or personal seal to the Sign-in Card and submit it for registration on the day of the shareholders' meeting. If you wish to appoint a proxy to attend the meeting, please fill out the name and relevant information of the proxy, affix your signature or personal seal to the Proxy Form, have the proxy affix his or her signature or personal seal to the Proxy Form. Such proxy form shall be delivered to the Company's securities agent at the Register and Transfer Agency division of CTBC Bank Corporation, at least five (5) days prior to the meeting so that a sign-in card can be issued to the proxy.

IV. If any shareholder solicits proxies, the Company will publish a summary of such solicitation on the Securities and Futures Commission website (<http://free.sfi.org.tw>). For shareholders who wish to make inquiries, please access the "free inquiry system for published information on proxies" page on the website, click on "entrance to published information on proxies", and enter the search criteria.

- V. This annual general meeting allows shareholders to exercise their proxy votes by correspondence or by electronic means. Please login to the Taiwan Depository & Clearing Corporation stock vote platform website (<http://www.stockvote.com.tw>) to exercise your proxy vote between May 9th, 2018 to June 5th, 2018. Proxy forms and electronic voting auditing and verification services will be provided by the stock transfer division of CTBC Bank Corporation.
- VI. The institution responsible for tallying and verifying the votes for the Company is the Register and Transfer Agency division of CTBC Bank Corporation.

Sincerely Yours

The Board of Directors of TWi Pharmaceuticals, Inc.